Ibipinabant
Obesity and Type 2 Diabetes
Solvay PharmaceuticalsSmall moleculePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Obesity and Type 2 Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enavogliflozin Korea University Anam Hospital | Phase 4 | BB |
nt-0796 NodThera Limited | Phase 2 | B |
Trigonella Foenum-Graecum Seed Extract University of Hail | N/A | D |
Glipizide Washington University School of Medicine | N/A | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →